BamSEC and AlphaSense Join Forces
Learn More
You must log in to view this page.
You must log in to view this page.
You must log in to view this page.

Cytokinetics Incorporated

NASDAQ: CYTK    
Share price (10/21/25): $57.78    
Market cap (10/21/25): $6.914 billion
Search in Documents
Key Exhibits
External Links

Underwriting Agreements Filter

EX-1.2
from S-3ASR 42 pages Open Market Sale Agreementsm
12/34/56
EX-1.1
from 8-K 39 pages Cytokinetics, Incorporated 9,803,922 Shares of Common Stock Underwriting Agreement
12/34/56
EX-1.1
from 8-K 38 pages Cytokinetics, Incorporated 10,000,000 Shares of Common Stock Underwriting Agreement
12/34/56
EX-1.1
from 8-K 38 pages Cytokinetics, Incorporated 7,291,667 Shares of Common Stock Underwriting Agreement
12/34/56
EX-1.1
from 8-K 57 pages 4.00% Convertible Senior Notes Due 2026 Cytokinetics, Incorporated Underwriting Agreement
12/34/56
EX-1.1
from 10-K 50 pages Cytokinetics, Incorporated Shares of Common Stock (Par Value $0.001 Per Share) Controlled Equity Offeringsm Sales Agreement
12/34/56
EX-1.1
from 8-K 40 pages 5,260,000 Shares of Common Stock Cytokinetics, Incorporated Underwriting Agreement
12/34/56
EX-1.1
from 8-K 39 pages 4,375,000 Shares of Common Stock Cytokinetics, Incorporated Underwriting Agreement
12/34/56
EX-1.2
from 8-K 41 pages 23,026 Shares of Series B Convertible Preferred Stock Warrants to Purchase 13,815,600 Shares of Common Stock Cytokinetics, Incorporated Underwriting Agreement
12/34/56
EX-1.1
from 8-K 40 pages 55,921,055 Shares of Common Stock Warrants to Purchase 33,552,633 Shares of Common Stock Cytokinetics, Incorporated Underwriting Agreement
12/34/56
EX-1.1
from 8-K ~20 pages 7,106,600 Shares of Common Stock and Warrants to Purchase Up to 3,553,300 Shares of Common Stock Cytokinetics, Incorporated Placement Agent Agreement
12/34/56
EX-1
from SC 13D 21 pages Cytokinetics, Incorporated Common Stock Purchase Agreement
12/34/56
EX-1.1
from 8-K 46 pages 5,285,715 Shares Cytokinetics, Incorporated Common Stock Placement Agent Agreement
12/34/56
EX-1
from SC 13G 2 pages Joint Filing Agreement
12/34/56
EX-1
from SC 13G 1 page Exhibit 1 the Shares of the Issuer's Common Stock Reported as Beneficially Owned by Hbm Bioventures AG in This Schedule 13g Is Beneficially Owned, Directly or Indirectly, Through the Following Entities, Each of Which Is a Wholly-Owned Subsidiary of Hbm Bioventures AG: 1). Hbm Bioventures (Cayman) Ltd. 2). International Bm Biomedicine Holdings Inc. - 6
12/34/56
EX-1.1
from S-1/A ~20 pages Underwriting agreement
12/34/56